Exome sequencing of hepatoblastoma reveals novel mutations and cancer genes in the Wnt pathway and ubiquitin ligase complex

Hepatology

Volumn 60, Issue 5, 2014, Pages 1686-1696

  Jia, Deshui ^a   Dong, Rui ^b   Jing, Ying ^a,c   Xu, Dan ^a   Wang, Qifeng ^d   Chen, Lei ^e   Li, Qigen ^f   Huang, Yuping ^a   Zhang, Yuannv ^a   Zhang, Zhenfeng ^a   Liu, Li ^a   Zheng, Shan ^b   Xia, Qiang ^f   Wang, Hongyang ^e   Dong, Kuiran ^b   He, Xianghuo ^a  

^a SHANGHAI CANCER INSTITUTE   (China)

^b CHILDREN S HOSPITAL OF FUDAN UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

^d FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^e SECOND MILITARY MEDICAL UNIVERSITY   (China)

^f SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CAPRIN2 PROTEIN; CDC20B PROTEIN; CTNNB1 PROTEIN; KLHL22 PROTEIN; OR5I1 PROTEIN; PROTEIN; RNF169 PROTEIN; SHORT HAIRPIN RNA; SPOP PROTEIN; TRPC4AP PROTEIN; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; CDKN2B PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 2B; NUCLEAR PROTEIN; REPRESSOR PROTEIN; SPOP PROTEIN, HUMAN; WNT PROTEIN;

ADOLESCENT; ADULT; ARTICLE; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CHILD; CHROMOSOME; CLINICAL ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; EXOME; EXON; FEMALE; GAIN OF FUNCTION MUTATION; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; HEPATOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LOSS OF FUNCTION MUTATION; LYMPHOCYTE; MALE; MIDDLE AGED; MUTATION RATE; POINT MUTATION; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN FUNCTION; SCHOOL CHILD; SOMATIC MUTATION; TUMOR GENE; TUMOR SUPPRESSOR GENE; UPREGULATION; WNT SIGNALING PATHWAY; YOUNG ADULT; GENETICS; LIVER TUMOR; METABOLISM; NUCLEOTIDE SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; BETA CATENIN; CHILD; CHILD, PRESCHOOL; CYCLIN-DEPENDENT KINASE INHIBITOR P15; DNA COPY NUMBER VARIATIONS; DNA MUTATIONAL ANALYSIS; EXOME; FEMALE; HEPATOBLASTOMA; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; REPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASE COMPLEXES; WNT PROTEINS; YOUNG ADULT;

EID: 84922267671     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27243     Document Type: Article

References (44)

1. Spector LG, Birch J. The epidemiology of hepatoblastoma. Pediatr Blood Cancer 2012;59:776-779.
2. Herzog CE, Andrassy RJ, Eftekhari F. Childhood cancers: hepatoblastoma. Oncologist 2000;5:445-453.
3. Buendia MA. Genetic alterations in hepatoblastoma and hepatocellular carcinoma: common and distinctive aspects. Med Pediatr Oncol 2002;39:530-535.
4. Yeh YA, Rao PH, Cigna CT, Middlesworth W, Lefkowitch JH, Murty VV. Trisomy 1q, 2, and 20 in a case of hepatoblastoma: possible significance of 2q35-q37 and 1q12-q21 rearrangements. Cancer Genet Cytogenet 2000;123:140-143.
5. Curia MC, Zuckermann M, De Lellis L, Catalano T, Lattanzio R, Aceto G, et al. Sporadic childhood hepatoblastomas show activation of beta-catenin, mismatch repair defects and p53 mutations. Mod Pathol 2008;21:7-14.
6. Blaker H, Hofmann WJ, Rieker RJ, Penzel R, Graf M, Otto HF. Beta-catenin accumulation and mutation of the CTNNB1 gene in hepatoblastoma. Genes Chromosomes Cancer 1999;25:399-402.
7. Regel I, Eichenmuller M, Joppien S, Liebl J, Haberle B, Muller-Hocker J, et al. IGFBP3 impedes aggressive growth of pediatric liver cancer and is epigenetically silenced in vascular invasive and metastatic tumors. Mol Cancer 2012;11:9.
8. Zatkova A, Rouillard JM, Hartmann W, Lamb BJ, Kuick R, Eckart M, et al. Amplification and overexpression of the IGF2 regulator PLAG1 in hepatoblastoma. Genes Chromosomes Cancer 2004;39:126-137.
9. Teer JK, Mullikin JC. Exome sequencing: the sweet spot before whole genomes. Hum Mol Genet 2010;19:R145-151.
10. Robinson PN. Whole-exome sequencing for finding de novo mutations in sporadic mental retardation. Genome Biol 2010;11:144.
11. Yan XJ, Xu J, Gu ZH, Pan CM, Lu G, Shen Y, et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 2011;43:309-315.
12. Huang J, Deng Q, Wang Q, Li KY, Dai JH, Li N, et al. Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nat Genet 2012;44:1117-1121.
13. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012;44:685-689.
14. Jia D, Jing Y, Zhang Z, Liu L, Ding J, Zhao F, et al. Amplification of MPZL1/PZR promotes tumor cell migration through Src-mediated phosphorylation of cortactin in hepatocellular carcinoma. Cell Res 2014 24:204-217.
15. Parsons DW, Li M, Zhang X, Jones S, Leary RJ, Lin JC, et al. The genetic landscape of the childhood cancer medulloblastoma. Science 2011;331:435-439.
16. Zhang J, Benavente CA, McEvoy J, Flores-Otero J, Ding L, Chen X, et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 2012;481:329-334.
17. Wei Y, Fabre M, Branchereau S, Gauthier F, Perilongo G, Buendia MA. Activation of beta-catenin in epithelial and mesenchymal hepatoblastomas. Oncogene 2000;19:498-504.
18. Purcell R, Childs M, Maibach R, Miles C, Turner C, Zimmermann A, et al. HGF/c-Met related activation of beta-catenin in hepatoblastoma. J Exp Clin Cancer Res 2011;30:96.
19. Lopez-Terrada D, Gunaratne PH, Adesina AM, Pulliam J, Hoang DM, Nguyen Y, et al. Histologic subtypes of hepatoblastoma are characterized by differential canonical Wnt and Notch pathway activation in DLK+ precursors. Hum Pathol 2009;40:783-794.
20. Taniguchi K, Roberts LR, Aderca IN, Dong X, Qian C, Murphy LM, et al. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 2002;21:4863-4871.
21. Akiyama T. Wnt/beta-catenin signaling. Cytokine Growth Factor Rev 2000;11:273-282.
22. Ding Y, Xi Y, Chen T, Wang JY, Tao DL, Wu ZL, et al. Caprin-2 enhances canonical Wnt signaling through regulating LRP5/6 phosphorylation. J Cell Biol 2008;182:865-872.
23. Kwon JE, La M, Oh KH, Oh YM, Kim GR, Seol JH, et al. BTB domain-containing speckle-type POZ protein (SPOP) serves as an adaptor of Daxx for ubiquitination by Cul3-based ubiquitin ligase. J Biol Chem 2006;281:12664-12672.
24. Metzger T, Kleiss C, Sumara I. CUL3 and protein kinases: Insights from PLK1/KLHL22 interaction. Cell Cycle 2013;12.
25. Choi SH, Wright JB, Gerber SA, Cole MD. Myc protein is stabilized by suppression of a novel E3 ligase complex in cancer cells. Genes Dev 2010;24:1236-1241.
26. Poulsen M, Lukas C, Lukas J, Bekker-Jensen S, Mailand N. Human RNF169 is a negative regulator of the ubiquitin-dependent response to DNA double-strand breaks. J Cell Biol 2012;197:189-199.
27. Suzuki M, Kato M, Yuyan C, Takita J, Sanada M, Nannya Y, et al. Whole-genome profiling of chromosomal aberrations in hepatoblastoma using high-density single-nucleotide polymorphism genotyping microarrays. Cancer Sci 2008;99:564-570.
28. Stejskalova E, Malis J, Snajdauf J, Pycha K, Urbankova H, Bajciova V, et al. Cytogenetic and array comparative genomic hybridization analysis of a series of hepatoblastomas. Cancer Genet Cytogenet 2009;194:82-87.
29. Weber RG, Pietsch T, von Schweinitz D, Lichter P. Characterization of genomic alterations in hepatoblastomas. A role for gains on chromosomes 8q and 20 as predictors of poor outcome. Am J Pathol 2000;157:571-578.
30. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol 2011;12:R41.
31. Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007;450:893-898.
32. Rosen P, Sesterhenn IA, Brassell SA, McLeod DG, Srivastava S, Dobi A. Clinical potential of the ERG oncoprotein in prostate cancer. Nat Rev Urol 2012;9:131-137.
33. Dwyer JM, Liu JP. Ets2 transcription factor, telomerase activity and breast cancer. Clin Exp Pharmacol Physiol 2010;37:83-87.
34. He W, Li X, Xu S, Ai J, Gong Y, Gregg JL, et al. Aberrant methylation and loss of CADM2 tumor suppressor expression is associated with human renal cell carcinoma tumor progression. Biochem Biophys Res Commun 2013;435:526-532.
35. Chang PH, Hwang-Verslues WW, Chang YC, Chen CC, Hsiao M, Jeng YM, et al. Activation of Robo1 signaling of breast cancer cells by Slit2 from stromal fibroblast restrains tumorigenesis via blocking PI3K/Akt/beta-catenin pathway. Cancer Res 2012;72:4652-4661.
36. Goding CR. Fishful thinking: the rise and fall of MITF in melanoma. Pigment Cell Melanoma Res 2014;27:7-8.
37. Le Gallo M, O'Hara AJ, Rudd ML, Urick ME, Hansen NF, O'Neil NJ, et al. Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet 2012;44:1310-1315.
38. Soto Martinez JL, Cabrera Morales CM, Serrano Ortega S, Lopez-Nevot MA. Mutation and homozygous deletion analyses of genes that control the G1/S transition of the cell cycle in skin melanoma: p53, p21, p16 and p15. Clin Transl Oncol 2005;7:156-164.
39. Humeniuk R, Rosu-Myles M, Fares J, Koller R, Bies J, Wolff L. The role of tumor suppressor p15Ink4b in the regulation of hematopoietic progenitor cell fate. Blood Cancer J 2013;2:e99.
40. Cairo S, Armengol C, De Reynies A, Wei Y, Thomas E, Renard CA, et al. Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell 2008;14:471-484.
41. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998;67:425-479.
42. Nakayama KI, Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 2006;6:369-381.
43. Zhuang M, Calabrese MF, Liu J, Waddell MB, Nourse A, Hammel M, et al. Structures of SPOP-substrate complexes: insights into molecular architectures of BTB-Cul3 ubiquitin ligases. Mol Cell 2009;36:39-50.
44. An J, Wang C, Deng Y, Yu L, Huang H. Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants. Cell Rep 2014;6:657-669.